AUS
NZ
UK
CA
USA
IND
Healt
Is CSL (ASX:CSL) driving ASX 200 healthcare weakness?
April 22, 2026 05:40 PM AEST| By SamHealthcare sector movements and global developments influence ASX market sentiment, with large-cap stocks like CSL shaping broader index dynamics.
ASX 200 Shocker: Cochlear Crash Deepens After Earnings Blow
April 22, 2026 05:36 PM AEST| By SamCochlear shares plunge after a sharp earnings downgrade driven by global headwinds, policy pressures, and weaker demand, highlighting short-term challenges despite ongoing innovation and long-term healthcare demand.
ASX 200 Biotech Under Pressure: Can CSL Stage a Comeback?
April 22, 2026 05:31 PM AEST| By SamCSL faces pressure amid earnings challenges and market rotation, though strong plasma therapy demand and global positioning continue to support its long-term outlook within the healthcare sector.
Why CSL Is Back in Focus Across ASX 100
April 22, 2026 05:24 PM AEST| By SamCSL remains central to Australia’s healthcare sector, with its role in biotechnology and global medical supply shaping its position within major equity indices.
ASX 200 Healthcare Giant Plunges: What’s Behind Cochlear’s Shock Fall?
April 22, 2026 05:18 PM AEST| By SamCochlear shares drop after earnings downgrade driven by weaker demand, hospital constraints, and lower referrals, highlighting near-term pressure despite ongoing innovation and long-term healthcare market opportunities.
4DMedical All Ords Entry Gains Market Focus
April 22, 2026 05:05 PM AEST| By Sam4DMedical’s inclusion in the All Ordinaries highlights healthcare technology’s expanding role in Australian equities, reflecting innovation-led sector participation and evolving market composition.
ASX 200 Healthcare Stock Under Pressure: Cochlear Faces Sharp Earnings Reset
April 22, 2026 02:07 PM AEST| By SamCochlear Ltd (ASX: COH) has reset its earnings outlook following multiple headwinds, highlighting near-term challenges within the ASX healthcare stocks sector.
ASX Healthcare Stock Expands Capital Base with Massive Share Issuance
April 22, 2026 10:24 AM AEST| By SamPercheron Therapeutics’ large share issuance highlights a major capital restructuring move, with potential impacts on liquidity, ownership dynamics, and future growth strategy.
ASX 200 Healthcare Stocks Lag: Quiet Setup for Next Rally?
April 22, 2026 10:16 AM AEST| By SamASX 200 healthcare stocks lag behind tech recovery, but strong fundamentals and long-term demand highlight potential for future sector revival.
Why Is Recce Pharma’s Indonesia Milestone Gaining Attention?
April 21, 2026 06:51 PM AEST| By SamRecce Pharmaceuticals advances its clinical journey after a successful Indonesia inspection, reinforcing trial integrity and supporting expansion across Southeast Asia’s growing healthcare market.
What Lies Ahead for Starpharma After FDA Clears DEP HER2 Path?
April 21, 2026 05:22 PM AEST| By SamStarpharma progresses DEP HER2 into clinical development following FDA guidance, highlighting innovation in targeted cancer therapies and shaping its next growth phase in oncology research.
ASX 200 Welcomes New Healthcare Player as 4DMedical Joins the Index
April 21, 2026 04:13 PM AEST| By Sam4DMedical’s inclusion in the ASX 200 marks a key milestone, boosting visibility and reinforcing its position in the growing healthcare technology sector.
Why CSL Shares (ASX: CSL) Are Facing Volatility on the S&P/ASX 200
April 21, 2026 03:33 PM AEST| By SamCSL shares (ASX: CSL) have faced volatility due to growth revisions and sector trends, though long-term fundamentals remain supported by strong global healthcare demand.
Is Telix Pharma (ASX:TLX) in ASX 200 Market Focus?
April 21, 2026 12:45 PM AEST| By SamTelix Pharmaceuticals reflects valuation-focused attention within the ASX healthcare sector, highlighting biotechnology participation and trends across ASX 100 and ASX 200 indices.
ASX 100 Pharma Stock Sees Surge in Market Focus
April 21, 2026 12:40 PM AEST| By SamTelix Pharmaceuticals reflects positioning within ASX healthcare sector, highlighting biotechnology participation and trends across ASX 100 and ASX 200 indices.
Why Is Emyria Expanding Into Global Drug Services Now?
April 20, 2026 03:22 PM AEST| By SamEmyria introduces a global services platform targeting drug sponsors, unlocking new revenue opportunities while addressing growing demand for clinical delivery in advanced mental health therapies worldwide.
Why Is (ASX:RAD) Drawing Attention After Clinical Update?
April 20, 2026 03:14 PM AEST| By SamRadiopharm Theranostics shares gain attention as early trial data highlights tumour targeting and safety profile, marking a notable step in its oncology research journey.
Could This New Platform Redefine Global Clinical Trials?
April 20, 2026 02:24 PM AEST| By SamEmyria launches a global clinical platform to connect drug sponsors with scalable infrastructure, aiming to accelerate complex therapy trials and improve patient access worldwide.
Why ASX All Ords Stock OCC Draws Market Focus?
April 20, 2026 12:09 PM AEST| By SamOrthocell highlights strong quarterly activity with Remplir rollout expansion in the US, reflecting healthcare innovation and regenerative medicine developments within ASX All Ords.
This Healthcare ASX 300 Stock Just Dropped After Record High
April 20, 2026 11:59 AM AEST| By SamPro Medicus reflects movement after record highs, highlighting healthcare technology trends and trading activity across ASX 300 and broader market indices.
Advertise your brand on Kalkine Media